Shalini Sharp's most recent trade in Septerna Inc. was a trade of 16,623 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Septerna Inc. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 16,623 | 16,623 | - | - | Stock Option (Right to Buy) | |
| Organon & Co. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2025 | 23,904 | 63,054 | - | - | Phantom Stock | |
| BeiGene Ltd - ADR | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 22,750 | 22,750 | - | - | Share Option (Right to Buy) | |
| BeiGene Ltd - ADR | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 10,985 | 19,136 (0%) | 0% | 0 | Ordinary Shares | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 3,305 | 3,305 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 1,659 | 1,659 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 1,435 | 2,429 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 1,435 | 0 | - | - | Restricted Stock Unit | |
| BeiGene Ltd - ADR | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 17,238 | 17,238 | - | - | Share Option (Right to Buy) | |
| BeiGene Ltd - ADR | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 8,151 | 8,151 (0%) | 0% | 0 | Ordinary Shares | |
| Organon & Co. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 9,638 | 36,783 | - | - | Phantom Stock | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 2,982 | 2,982 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 1,435 | 1,435 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 2,100 | 0 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 2,100 | 2,100 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Sale of securities on an exchange or to another person at price $ 141.90 per share. | 17 May 2024 | 1,106 | 994 (0%) | 0% | 141.9 | 156,943 | Common Stock |
| Organon & Co. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 10,086 | 25,594 | - | - | Phantom Stock | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 4,290 | 4,290 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 2,100 | 2,100 | - | - | Restricted Stock Unit | |
| Mirati Therapeutics Inc | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 7,520 | 7,520 | - | - | Non Qualified Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 4,444 | 9,414 (0%) | 0% | 0 | Common Stock | |
| Organon & Co. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 5,640 | 14,935 | - | - | Phantom Stock | |
| Sutro Biopharma Inc | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 18,500 | 18,500 | - | - | Stock Option (right to buy) | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 9,724 | 9,724 | - | - | Non-Qualified Stock Option | |
| Mirati Therapeutics Inc | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 3,688 | 3,688 | - | - | Non Qualified Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 2,546 | 4,970 (0%) | 0% | 0 | Common Stock | |
| Organon & Co. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 9,061 | 9,061 | - | - | Phantom Stock | |
| Sutro Biopharma Inc | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 18,500 | 18,500 | - | - | Stock Option (right to buy) | |
| Neurocrine Biosciences, Inc. | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2021 | 8,833 | 8,833 | - | - | Non-Qualified Stock Option | |
| Precision Biosciences Inc | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2021 | 32,800 | 32,800 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | EVP, Finance | Sale of securities on an exchange or to another person at price $ 87.99 per share. | 14 Oct 2020 | 375 | 97,812 (0%) | 0% | 88.0 | 32,996 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Sale of securities on an exchange or to another person at price $ 88.38 per share. | 17 Aug 2020 | 7,188 | 98,187 (0%) | 0% | 88.4 | 635,275 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2020 | 7,188 | 15,812 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.55 per share. | 17 Aug 2020 | 7,188 | 105,375 (0%) | 0% | 67.5 | 485,549 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2020 | 3,669 | 15,312 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Sale of securities on an exchange or to another person at price $ 88.38 per share. | 17 Aug 2020 | 3,669 | 98,187 (0%) | 0% | 88.4 | 324,266 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 48.43 per share. | 17 Aug 2020 | 3,669 | 101,856 (0%) | 0% | 48.4 | 177,690 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Sale of securities on an exchange or to another person at price $ 88.54 per share. | 17 Aug 2020 | 2,560 | 98,187 (0%) | 0% | 88.5 | 226,662 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Sale of securities on an exchange or to another person at price $ 88.38 per share. | 17 Aug 2020 | 500 | 98,187 (0%) | 0% | 88.4 | 44,190 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 70.57 per share. | 17 Aug 2020 | 500 | 98,687 (0%) | 0% | 70.6 | 35,285 | Common Stock |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2020 | 500 | 0 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Shalini Sharp | CFO & Executive Vice President | Sale of securities on an exchange or to another person at price $ 88.24 per share. | 17 Aug 2020 | 461 | 100,747 (0%) | 0% | 88.2 | 40,679 | Common Stock |